vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $207.8M, roughly 1.6× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 17.0%, a 40.4% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-90.4M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
IDYA vs PRAA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $333.4M |
| Net Profit | $119.2M | $56.5M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 37.7% |
| Net Margin | 57.4% | 17.0% |
| Revenue YoY | — | 13.7% |
| Net Profit YoY | 330.1% | 206.3% |
| EPS (diluted) | $1.33 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $333.4M | ||
| Q3 25 | $207.8M | $311.1M | ||
| Q2 25 | — | $287.7M | ||
| Q1 25 | — | $269.6M | ||
| Q4 24 | — | $293.2M | ||
| Q3 24 | $0 | $281.5M | ||
| Q2 24 | $0 | $284.2M | ||
| Q1 24 | $0 | $255.6M |
| Q4 25 | — | $56.5M | ||
| Q3 25 | $119.2M | $-407.7M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $-51.8M | $27.2M | ||
| Q2 24 | $-52.8M | $21.5M | ||
| Q1 24 | $-39.6M | $3.5M |
| Q4 25 | — | 37.7% | ||
| Q3 25 | 52.2% | -101.4% | ||
| Q2 25 | — | 29.6% | ||
| Q1 25 | — | 27.7% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 32.0% | ||
| Q2 24 | — | 31.4% | ||
| Q1 24 | — | 26.0% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | 57.4% | -131.0% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 9.6% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | $1.47 | ||
| Q3 25 | $1.33 | $-10.43 | ||
| Q2 25 | — | $1.08 | ||
| Q1 25 | — | $0.09 | ||
| Q4 24 | — | $0.47 | ||
| Q3 24 | $-0.60 | $0.69 | ||
| Q2 24 | $-0.68 | $0.54 | ||
| Q1 24 | $-0.53 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $979.9M |
| Total Assets | $1.2B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $104.4M | ||
| Q3 25 | $786.9M | $107.5M | ||
| Q2 25 | — | $131.6M | ||
| Q1 25 | — | $128.7M | ||
| Q4 24 | — | $105.9M | ||
| Q3 24 | $920.0M | $141.1M | ||
| Q2 24 | $701.7M | $118.9M | ||
| Q1 24 | $698.8M | $108.1M |
| Q4 25 | — | $979.9M | ||
| Q3 25 | $1.1B | $928.5M | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $931.7M | $1.1B | ||
| Q1 24 | $935.3M | $1.1B |
| Q4 25 | — | $5.1B | ||
| Q3 25 | $1.2B | $5.0B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.1B | ||
| Q4 24 | — | $4.9B | ||
| Q3 24 | $1.2B | $4.9B | ||
| Q2 24 | $973.7M | $4.7B | ||
| Q1 24 | $961.5M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $-85.5M |
| Free Cash FlowOCF − Capex | $142.2M | $-90.4M |
| FCF MarginFCF / Revenue | 68.4% | -27.1% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.19× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-85.5M | ||
| Q3 25 | $142.2M | $-10.1M | ||
| Q2 25 | — | $-12.9M | ||
| Q1 25 | — | $-52.6M | ||
| Q4 24 | — | $-94.6M | ||
| Q3 24 | $-49.2M | $-35.0M | ||
| Q2 24 | $-32.9M | $-29.5M | ||
| Q1 24 | $-43.8M | $-73.0M |
| Q4 25 | — | $-90.4M | ||
| Q3 25 | $142.2M | $-11.3M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-53.5M | ||
| Q4 24 | — | $-98.6M | ||
| Q3 24 | $-49.7M | $-36.1M | ||
| Q2 24 | $-33.9M | $-30.8M | ||
| Q1 24 | $-45.1M | $-73.5M |
| Q4 25 | — | -27.1% | ||
| Q3 25 | 68.4% | -3.6% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | — | -12.8% | ||
| Q2 24 | — | -10.8% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | -1.51× | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | — | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | — | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
